TY - JOUR
T1 - RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma
T2 - Their distribution patterns and biologic significance
AU - Siar, Chong Huat
AU - Tsujigiwa, Hidetsugu
AU - Ishak, Ismadi
AU - Hussin, Nurmawarnis Mat
AU - Nagatsuka, Hitoshi
AU - Ng, Kok Han
N1 - Funding Information:
This study was jointly supported by the Ministry of Higher Education Malaysia Fundamental Research Grant Scheme ( FP038-2013 A ), Japan Society for Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (C26462783) and Grant-in-Aid for Research Activity Start-up (25893141).
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives To determine the distribution patterns of bone resorption regulators, receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in recurrent ameloblastoma (RAs) and to clarify their impact on the biologic behavior of these neoplasms.Materials and Methods Fifteen paraffin-embedded RA cases were subjected to immunohistochemistry for expression of RANK, RANKL, and OPG.Results The RANK-RANKL-OPG triad was heterogeneously detected in RA samples. RANK, essential for osteoclast differentiation, was strongly expressed in tumoral epithelium. Conversely, RANKL, an osteoclast activator, was markedly underexpressed, and protein localization was predominantly stromal. OPG, an osteoclastogenesis inhibitory factor, was detected in neoplastic epithelium more than in stroma, suggesting functional inactivation of RANKL. Most RA (n = 12/15; 80%) exhibited a bimolecular spatial expression pattern, the most common being RANK-positive/OPG-positive (n = 8/15; 53.3%). All three proteins showed no significant correlation with the clinical/histopathologic parameters in RA patients (P >.05).Conclusions The RANK+/RANKLlow/-/OPG+ phenotype observed in RA suggests an altered local bone metabolism characterized by low bone resorptive activity in these recurrent tumors.
AB - Objectives To determine the distribution patterns of bone resorption regulators, receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in recurrent ameloblastoma (RAs) and to clarify their impact on the biologic behavior of these neoplasms.Materials and Methods Fifteen paraffin-embedded RA cases were subjected to immunohistochemistry for expression of RANK, RANKL, and OPG.Results The RANK-RANKL-OPG triad was heterogeneously detected in RA samples. RANK, essential for osteoclast differentiation, was strongly expressed in tumoral epithelium. Conversely, RANKL, an osteoclast activator, was markedly underexpressed, and protein localization was predominantly stromal. OPG, an osteoclastogenesis inhibitory factor, was detected in neoplastic epithelium more than in stroma, suggesting functional inactivation of RANKL. Most RA (n = 12/15; 80%) exhibited a bimolecular spatial expression pattern, the most common being RANK-positive/OPG-positive (n = 8/15; 53.3%). All three proteins showed no significant correlation with the clinical/histopathologic parameters in RA patients (P >.05).Conclusions The RANK+/RANKLlow/-/OPG+ phenotype observed in RA suggests an altered local bone metabolism characterized by low bone resorptive activity in these recurrent tumors.
UR - http://www.scopus.com/inward/record.url?scp=84915822030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84915822030&partnerID=8YFLogxK
U2 - 10.1016/j.oooo.2014.09.017
DO - 10.1016/j.oooo.2014.09.017
M3 - Article
C2 - 25446507
AN - SCOPUS:84915822030
SN - 2212-4403
VL - 119
SP - 83
EP - 91
JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
IS - 1
ER -